Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 145, Issue 6, 2013, Pages

  Later, Alexander F L ^a   Sitniakowsky, Laura S ^b   Van Hilten, Joost A ^b   Watering, Leo Van De ^b   Brand, Anneke ^a,b   Smit, Nico P M ^a   Klautz, Robert J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanquin Bloedbank Regio Zuidwest Rotterdam   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; APROTININ; CD135 ANTIGEN; GROWTH DIFFERENTIATION FACTOR 3; GROWTH DIFFERENTIATION FACTOR 5; INTERFERON ALPHA8; INTERLEUKIN 1; INTERLEUKIN 1 FAMILY MEMBER 7; INTERLEUKIN 19; MESSENGER RNA; PLACEBO; TRANEXAMIC ACID; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR SUPERFAMILY 10; TUMOR NECROSIS FACTOR SUPERFAMILY 12; TUMOR NECROSIS FACTOR SUPERFAMILY 13B; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HEART SURGERY; HUMAN; LOADING DRUG DOSE; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; UPREGULATION;

EID: 84877810645     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.11.042     Document Type: Article

References (27)

1. D.A. Henry, A.J. Moxey, P.A. Carless, D. O'Connell, K.M. McClelland, and K.M. Henderson Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion Cochrane Database Syst Rev 4 1999 CD001886
2. M.D. McEvoy, S.T. Reeves, J.G. Reves, and F.G. Spinale Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action Anesth Analg 105 2007 949 962
3. M. Levi, and T. Van Der Poll Inflammation and coagulation Crit Care Med 38 2010 S26 S34
4. J.R. Day, K.M. Taylor, E.A. Lidington, J.C. Mason, D.O. Haskard, and A.M. Randi Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1 J Thorac Cardiovasc Surg 131 2006 21 27
5. T.Y. Hsia, T.C. McQuinn, R. Mukherjee, R.L. Deardorff, J.E. Squires, and R.E. Stroud Effects of aprotinin or tranexamic acid on proteolytic/cytokine profiles in infants after cardiac surgery Ann Thorac Surg 89 2010 1843 1852
6. E.M. Graham, A.M. Atz, J. Gillis, S.M. Desantis, A.L. Haney, and R.L. Deardorff Differential effects of aprotinin and tranexamic acid on outcomes and cytokine profiles in neonates undergoing cardiac surgery J Thorac Cardiovasc Surg 143 2012 1069 1076
7. K. Karkouti, W.S. Beattie, K.M. Dattilo, S.A. McCluskey, M. Ghannam, and A. Hamdy A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery Transfusion 46 2006 327 338
8. D.T. Mangano, Y. Miao, A. Vuylsteke, I.C. Tudor, R. Juneja, and D. Filipescu Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery JAMA 297 2007 471 479
9. D.A. Fergusson, P.C. Hebert, C.D. Mazer, S. Fremes, C. MacAdams, and J.M. Murkin A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2008 2319 2331
10. A.F. Later, J.J. Maas, F.H. Engbers, M.I. Versteegh, E.F. Bruggemans, and R.A. Dion Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial Eur J Cardiothorac Surg 36 2009 322 329
11. H.J. Robertshaw An anti-inflammatory role for tranexamic acid in cardiac surgery? Crit Care 12 2008 105
12. A. DeAnda Jr., and B.D. Spiess Aprotinin revisited J Thorac Cardiovasc Surg 144 2012 998 1002
13. D. Royston, B.P. Bidstrup, K.M. Taylor, and R.N. Sapsford Effect of aprotinin on need for blood transfusion after repeat open-heart surgery Lancet 2 1987 1289 1291
14. N.P. Dowd, J.M. Karski, D.C. Cheng, J.A. Carroll, Y. Lin, and R.L. James Pharmacokinetics of tranexamic acid during cardiopulmonary bypass Anesthesiology 97 2002 390 399
15. American College of Chest Physicians/Society of Critical Care Medicine Conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Chest 101 1992 1644 1655
16. W.A. Knaus, E.A. Draper, D.P. Wagner, and J.E. Zimmerman Prognosis in acute organ-system failure Ann Surg 202 1985 685 693
17. A.M. Mengistu, K.D. Rohm, J. Boldt, J. Mayer, S.W. Suttner, and S.N. Piper The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery Anesth Analg 107 2008 391 397
18. A.M. Calafiore, G. Teodori, G.G. Di, G. Bosco, A. Mezzetti, and D. Lapenna Intermittent antegrade cardioplegia: warm blood vs cold crystalloid: a clinical study J Cardiovasc Surg (Torino) 35 1994 179 184
19. A. Sablotzki, I. Friedrich, J. Muhling, M.G. Dehne, J. Spillner, and R.E. Silber The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions Perfusion 17 2002 103 109
20. R.J. Porte, and F.W. Leebeek Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery Drugs 62 2002 2193 2211
21. V. Casati, D. Guzzon, M. Oppizzi, F. Bellotti, A. Franco, and C. Gerli Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions J Thorac Cardiovasc Surg 120 2000 520 527
22. J.M. Murkin, F. Falter, J. Granton, B. Young, C. Burt, and M. Chu High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients Anesth Analg 110 2010 350 353
23. D. Pruefer, J. Makowski, M. Dahm, S. Guth, H. Oelert, and H. Darius Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion Ann Thorac Surg 75 2003 210 215
24. P.E. Greilich, C.F. Brouse, C.W. Whitten, L. Chi, J.M. Dimaio, and M.E. Jessen Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin J Thorac Cardiovasc Surg 126 2003 1498 1503
25. P. Tassani, N. Augustin, A. Barankay, S.L. Braun, F. Zaccaria, and J.A. Richter High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery J Cardiothorac Vasc Anesth 14 2000 682 686
26. J.J. Jimenez, J.L. Iribarren, L. Lorente, J.M. Rodriguez, D. Hernandez, and I. Nassar Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial Crit Care 11 2007 R117
27. K.L. Jones, D.M. de Kretser, S. Patella, and D.J. Phillips Activin A and follistatin in systemic inflammation Mol Cell Endocrinol 225 2004 119 125